Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
Company remains on track to report topline results in Spring 2018 DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to
View HTML
Toggle Summary Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
- Positive topline results from pivotal LEAP 1 trial announced in September, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $112.7 million cash and investments as of September 30, 2017 - DUBLIN, Ireland , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
View HTML
Toggle Summary Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
View HTML
Toggle Summary Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share.
View HTML
Toggle Summary Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $80.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an
View HTML
Toggle Summary Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
- Lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile -   - Conference call and webcast today at 8:30 a.m. EDT to review results - DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage
View HTML
Toggle Summary Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D.
Colin Broom, M.D. to serve as interim chief medical officer DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com